Sugi Predict

Sugi Predict / Compounds / SCHEMBL1377574

SCHEMBL1377574

SCHEMBL1377574

O=C(O)CCC(CN(O)C(=O)CCCc1ccccc1)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 7/20 0.58
▸ KDM4A O75164 1/20 0.57
▸ KDM5A P29375 1/20 0.57
▸ KDM4C Q9H3R0 1/20 0.57
▸ PHF8 Q9UPP1 1/20 0.57
▸ KDM2A Q9Y2K7 1/20 0.57
▸ CPA3 P15088 1/20 0.54
▸ HDAC3 O15379 2/20 0.53
▸ HDAC1 Q13547 2/20 0.53
▸ HDAC2 Q92769 2/20 0.53
▸ HDAC8 Q9BY41 2/20 0.53
▸ HDAC6 Q9UBN7 2/20 0.53
▸ HDAC5 Q9UQL6 2/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ ADRA1A P35348 1/20 0.53
▸ HDAC4 P56524 1/20 0.53
▸ SLC6A3 Q01959 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ HDAC7 Q8WUI4 1/20 0.53
▸ HDAC10 Q969S8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1373532 0.92 CPA3 (0.56) ALOX5KDM4AKDM5AKDM4CPHF8
SCHEMBL2368738 0.87 CPA3 (0.51) ALOX5KDM4AKDM5AKDM4CPHF8
SCHEMBL1374778 0.85 CPA3 (0.58) ALOX5CPA3
SCHEMBL2368874 0.81 CPA3 (0.54) ALOX5KDM4AKDM5AKDM4CPHF8
SCHEMBL31379020 0.80 ALOX5 (0.61) ALOX5KDM4AKDM5AKDM4CPHF8
SCHEMBL9835783 0.79 ALOX5 (0.67) ALOX5KDM4AKDM5AKDM4CPHF8
SCHEMBL10692283 0.77 ALOX5 (0.79) ALOX5KDM4AKDM5AKDM4CPHF8
SCHEMBL2368373 0.77 CPA3 (0.55) CPA3
SCHEMBL31379023 0.77 ALOX5 (0.56) ALOX5KDM4AKDM5AKDM4CPHF8
SCHEMBL7350860 0.76 CPA3 (0.71) CPA3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0973731-B1 HYDROXAMIC ACID DERIVATIVES GUILFORD PHARM INC (US) 2002-08-28 — — EP claimed
US-6395718-B1 RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS GUILFORD PHARMACEUTICALS INC. 2002-05-28 — — US claimed
JP-2002514185-A — — 2002-05-14 — — JP claimed
US-20010044459-A1 Hydroxamic acid derivatives JACKSON PAUL F (US) 2001-11-22 — — US claimed
JP-2001519809-A — — 2001-10-23 — — JP claimed
EP-0973731-A1 HYDROXAMIC ACID DERIVATIVES GUILFORD PHARMACEUTICALS INC. (US) 2000-01-26 — — EP claimed
US-5977090-A Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors GUILFORD PHARMACEUTICALS INC. (US) 1999-11-02 — — US claimed
EP-0949922-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-10-20 — — EP claimed
WO-1998045256-A1 HYDROXAMIC ACID DERIVATIVES GUILFORD PHARMACEUTICALS INC. (US) 1998-10-15 — — WO claimed
WO-1998013044-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 — — WO claimed
US-20230346752-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION 2023-11-02 — — US disclosed
US-20230293497-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION (US) 2023-09-21 — — US disclosed
US-11717514-B2 PSMA binding ligand-linker conjugates and methods for using PURDUE RESEARCH FOUNDATION (US) 2023-08-08 — — US disclosed
US-20230000836-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION 2023-01-05 — — US disclosed
US-11369590-B2 PSMA binding ligand-linker conjugates and methods for using PURDUE RESEARCH FOUNDATION (US) 2022-06-28 — — US disclosed
EP-0973731-A1 HYDROXAMIC ACID DERIVATIVES GUILFORD PHARMACEUTICALS INC. (US) 2000-01-26 — — EP disclosed
US-5977090-A Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors GUILFORD PHARMACEUTICALS INC. (US) 1999-11-02 — — US disclosed
EP-0949922-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-10-20 — — EP disclosed
WO-1998045256-A1 HYDROXAMIC ACID DERIVATIVES GUILFORD PHARMACEUTICALS INC. (US) 1998-10-15 — — WO disclosed
WO-1998013044-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293497-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 ALOX5 4272/4885KDM4A 2370/4885KDM5A 2429/4885
US-11369590-B2 PSMA binding ligand-linker conjugates and methods for using FOLH1, KLK3, PSMA1 ALOX5 4272/4885KDM4A 2370/4885KDM5A 2429/4885
US-20230000836-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 ALOX5 4272/4885KDM4A 2370/4885KDM5A 2429/4885
US-20010044459-A1 Hydroxamic acid derivatives NAALAD2, DNPEP, NAAA ALOX5 2026/4885KDM4A 1130/4885KDM5A 516/4885
US-11717514-B2 PSMA binding ligand-linker conjugates and methods for using FOLH1, KLK3, PSMA1 ALOX5 4272/4885KDM4A 2370/4885KDM5A 2429/4885
US-20230346752-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 ALOX5 4272/4885KDM4A 2370/4885KDM5A 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.